Globus Medical Inc (GMED) Shares Bought by Meadow Creek Investment Management LLC

Meadow Creek Investment Management LLC raised its position in shares of Globus Medical Inc (NYSE:GMED) by 18.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,492 shares of the medical device company’s stock after acquiring an additional 1,768 shares during the quarter. Meadow Creek Investment Management LLC’s holdings in Globus Medical were worth $472,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. BlackRock Inc. boosted its position in Globus Medical by 2.1% during the fourth quarter. BlackRock Inc. now owns 7,799,617 shares of the medical device company’s stock valued at $320,565,000 after acquiring an additional 159,963 shares during the last quarter. Janus Henderson Group PLC boosted its position in shares of Globus Medical by 18.6% during the 3rd quarter. Janus Henderson Group PLC now owns 3,181,499 shares of the medical device company’s stock worth $94,554,000 after purchasing an additional 498,187 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Globus Medical by 1.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,843,340 shares of the medical device company’s stock worth $54,784,000 after purchasing an additional 32,034 shares in the last quarter. NWQ Investment Management Company LLC boosted its position in shares of Globus Medical by 43.1% during the 4th quarter. NWQ Investment Management Company LLC now owns 1,245,219 shares of the medical device company’s stock worth $51,179,000 after purchasing an additional 375,234 shares in the last quarter. Finally, AXA boosted its position in shares of Globus Medical by 23.6% during the 4th quarter. AXA now owns 930,009 shares of the medical device company’s stock worth $38,223,000 after purchasing an additional 177,803 shares in the last quarter. 65.92% of the stock is currently owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

Shares of Globus Medical Inc (NYSE GMED) opened at $49.07 on Monday. Globus Medical Inc has a fifty-two week low of $27.79 and a fifty-two week high of $52.18. The firm has a market cap of $4,729.17, a PE ratio of 37.17, a P/E/G ratio of 2.72 and a beta of 0.44.

Globus Medical (NYSE:GMED) last posted its earnings results on Wednesday, February 21st. The medical device company reported $0.38 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.35 by $0.03. Globus Medical had a net margin of 16.88% and a return on equity of 13.93%. The company had revenue of $176.03 million for the quarter, compared to analyst estimates of $175.50 million. During the same quarter in the prior year, the business posted $0.31 EPS. The firm’s revenue was up 16.1% compared to the same quarter last year. equities research analysts forecast that Globus Medical Inc will post 1.5 earnings per share for the current year.

GMED has been the topic of a number of research analyst reports. BTIG Research set a $45.00 price objective on shares of Globus Medical and gave the stock a “buy” rating in a research report on Tuesday, January 2nd. Morgan Stanley set a $53.00 price objective on shares of Globus Medical and gave the stock a “buy” rating in a research report on Thursday, February 22nd. Zacks Investment Research raised shares of Globus Medical from a “hold” rating to a “buy” rating and set a $54.00 price objective on the stock in a research report on Monday, February 26th. ValuEngine raised shares of Globus Medical from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. Finally, Canaccord Genuity reissued a “buy” rating and set a $53.00 price objective on shares of Globus Medical in a research report on Monday, March 12th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and nine have issued a buy rating to the stock. Globus Medical currently has a consensus rating of “Buy” and a consensus price target of $49.57.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3301801/globus-medical-inc-gmed-shares-bought-by-meadow-creek-investment-management-llc.html.

Globus Medical Company Profile

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.

Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical Inc (NYSE:GMED).

Institutional Ownership by Quarter for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Liberum Capital Reiterates Hold Rating for Intu Properties
Liberum Capital Reiterates Hold Rating for Intu Properties
Peel Hunt Reaffirms “Buy” Rating for JD Sports Fashion
Peel Hunt Reaffirms “Buy” Rating for JD Sports Fashion
FY2019 Earnings Forecast for Roots Corporation  Issued By Jefferies Group
FY2019 Earnings Forecast for Roots Corporation Issued By Jefferies Group
FY2019 EPS Estimates for NICE Systems Ltd. Lifted by Analyst
FY2019 EPS Estimates for NICE Systems Ltd. Lifted by Analyst
Continental Resources, Inc.  to Post Q1 2019 Earnings of $0.86 Per Share, Piper Jaffray Forecasts
Continental Resources, Inc. to Post Q1 2019 Earnings of $0.86 Per Share, Piper Jaffray Forecasts
VEON  Shares Gap Up to $2.53
VEON Shares Gap Up to $2.53


© 2006-2018 Ticker Report. Google+.